Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Almost all of the longs are way under water, or new to AMBS, I am not sure which, the company would know. The pps would not even budge on the heels of a very positive announcement because of the finances of this company. Dilution.
OTOH, the army is going to throw money at this. They won't throw all of it, so AMBS will have to come up with cash. There is no doubt about that.
Actually they did, and said that they needed more data. My comment at the time was that the study was the more data.
maybe someone can find them. after search I was not able to do that
They declined to fund it this time, saying that they needed more data.
ESS is just brilliant. Yes there has been trouble around this asset but not because the asset doesn't work. Rather the trials were mismanaged. What does this create? Opportunity! And Gerald ceased it- He recently finalized the acquisition and managed to do this for pennies on the dollar. With trials slated to start in either Q3 or Q4 look to see a steady update on how the effectiveness of ESS is performing. If it is close to what its potential is then we will see in my opinion national attention.
This is the only paragraph that is close to being accurate. However GC seized the opportunity, he did not ceased it.
And it only takes one, so this is it, however, the company needs cash so they may well be taken to the shark tank and eaten. We will see.
aha, that would be why MJFF did not fund eltoprazine, and why they disagreed with AMBS over the effect of MANF on PD cells. That disagreement required an amended press release dated Nov 2012.
https://listingcenter.nasdaq.com/assets/initialguide.pdf
The Naz has some standards that say the company would only have to be trading at $2.
I really do not know if the company meets those standards, but it is an interesting set of different criteria.
As you know, MANF has not been tested in PD yet. That was a bit of sarcasm.
But I bet that therapy will be better than MANF. They continue to say that MANF improved the pathology, and that was never the case according to MJFF. A major blockade to funding MANF, by the way.
A new therapy for Parkinson's
http://www.philly.com/philly/health/sportsmedicine/One-two_punch_to_Parkinsons_Patients_get_relief_from_boxing_therapy.html
Boxing.
Its been tested to be better than MANF. Frankly, this is very interesting Therapy because it sounds better than any medicine to date. Get them up and boxing, or dancing, even though their body is resisting. I think the fellow in the article is in better shape than most of us.
Well, you never pick a time and a price, you pick one or the other, if you want to come close.
Here, you will know it when the pps bases.
The pps was at this level three years ago, and went all the way down to .007 cents. ( I believe that was the low. )
.007 cents is a dollar. That level could hold, or it could break, you never know.
The only thing I am sure of is this. At some point it will base for about six weeks, as the selling finishes.
And there is no reason to think that this RS dilute, RS dilute cycle will not repeat. They have a long way to go before any revenue.
They really need to sell ESS, their only asset that should clearly bring in cash. Hopefully, they will see significant money from that along with a royalty.
I am here for the trades, AMBS is a great trading stock.
AMBS will be a great trade sometime in the next few months, it was for some when it went from 4 to 7 cents just a while ago.
The last time I tried to catch a falling knife, I got cut.
They must know something that we don't
actualy, I think there will never be much revenue from Lympro. It could be used in research, but the only study that is using it has ties to AMBS.
ah, the pps is less than $4, there will be no Nasdaq.
This company needs to do something quick. Everyone knows that Lympro is not the answer. The Georgetown people are waiting for the $10 million to study their test.
ESS is the only path to quick money and an ACTUAL company that is still around.
If they can sell ESS, they need to do that now.
And when it gets there, they will need Billions of shares again, and not millions.
Who will GC and company get to buy their diluting shares? Only the shadow knows.
$10 million for the Georgetown test.
$$$ for ESS. Now they will probably sell ESS outright, and get a royalty. There is no money to develop this product.
Sell this, sell that, put a little makeup on the unwanted product and see who salutes.
$1 Billion for MANF, and so on and so forth.
I really didn't. That is a tripling of the A/S, and I thought the As was around 8 million at the time of the RS.
This thing is going back to penny land in that case.
AUTHORIZED SHARES OF COMMON STOCK FROM 13,333,333 TO 35,000,000.: Against
I didn't know they had gotten to 13 million already. A/S
Right, if GC had a pr TO KEEP THE PPS ABOVE $4 HE WOULD HAVE sent it out. That said, the pps has been on a deep dive for a long time.
This is an easy stock to trade. Just wait for the basing of the pps and then trade it when it moves up.
It based for awhile at 4+ cents and made a very tradeable move to 7 cents.
But all along, it was on its way to three cents, which WAS support. Now that support is demolished as the pps is $0.0228. A little over two cents.
In 2012 between June and November the pps got down to .007 cents. That would be $1.05
So unless the pps bases before it gets to $1 I would not try to trade it.
Saving a significant move on the back of ESS, the stock is NOT uplisting.
ah, the pps is not going to get you to the Naz any time soon, in addition the imminent dilution will take the pps down further.
They are trying to use the Lympro PRs to boost the pps. Why not try to use the Georgetown test which is better? Granted they do not own it yet, but well, that will be more likely to bring in cash than Lympro.
GC and company have been trying to move the pps with lympro and it never works because it cannot work. Even if you have someone else doing the talking.
Now, the ESS should bring in cash but they will have to give it away for the most part. It only takes one, if you can make enough money from it.
When the number of buys is eclipsed by the number of sellers, the price goes down. If the numbers were always equal, there would be very little reason for the price to go up or down.
0.0244 cents a share.
Only the most diehard AMBS fan is above water, or someone who took a stab and caught a falling knife today. The falling knife buyers couldbe up by as much as .20, if they are lucky, more or less, the cost of the trade.
By the partly unintelligible message after GC presented rehashed data as new GC was couting on this PR to pop the stock.
Ooops, we saw the data for what it was OLD, and that was that.
Now, he is right, if you combine Lympro with clinical, it could be helpful, but Opko has a test of similiar utility, numbers in the 70s.
Personally temperatures in the 70s are wonderful, but numbers in the 70s make the test only useful for research. Period.
You don't see ANY patient get the apo - e gene test, but 25 years later, they are still using it in research. IOW, the research angle may be a reasonable source of income.
lol, AMBS has everything that no one else wants. It is all smoke and mirrors. Keep it going, get as much in salary as we can, and hope that someone eventually buys MANF.
Eltoprazine cannot be studied, nor can any other key asset, without outside help.
Now, ESS should be an advance in wound care, so that could be the one, and it only takes one.
And where are they going to get the money for that, a Phase III study is extremely expensive, there is really no need for another drug on the market, and so on.
Now, it is always reasonable to have another drug on the market, but well, good luck getting the money to fund that one.
I have not looked at the studies regarding Eltoprazine and ADHD, but well, even the company is not headling Eltoprazine for this purpose.
I do not understand, the Georgetown test has much better numbers than Lympro ever has or will. What is up with this?
Apparently nothing is going to happen on August 3rd. Just posting again, to see if I missed something. I guess not.
https://www.google.com/finance?q=OTCMKTS%3AAMBS&ei=S7K2VcjtJ5akebusl_gP
What is the trend in this chart? Down, and it has not based yet. It may be basing, but with the diluting events coming up, you have to wonder when the pps will start to go UP.
What is going to happen on August 3rd?
Yes, one is the float, and the other is what the float is going to be soon, for AMBS. And you know that.
Well, it is a dilutive life preserver. It is more of the same, with a different label attached.
Now it is a better label in a better neighborhood, so that is good.
aha, well, they can twist words all they want, it is a secondary coming after many offerings in the public market.
The company is already public, it cannot go public twice. Then it would be more public than any other company and they do not allow that.
It is probably time to buy, as a trade. Everyone is very upset with the company.
"With an additional biological measure being added to the clinical diagnosis reference standard that improves accuracy vs. Autopsey to over 80% with PET (through long term studies that were done by Eli Lilly)?"
That sentence is actually poorly written. So first they are adding clinical to lympro, and hoping to get over 80%, and then somehow PET is in there somehow.
Poorly written release from a desperate CEO talking dead head.
rehash bad old news and you get a sell off, put that in your phenoguard and see what brews up.
Aha, PET scan 70%, that is a new one. It is clear that the AMBS community is wising up. Go retail investors. And GC notes that there is just one company in on Lympro and that company has ties to AMBS.
OMG the stock is back to three cents, I missed the boat. This is a sell off on about three tims volume today. IOW about 22 million unRS shares.